GW Pharma Limited (United Kingdom) and Otsuka Pharmaceutical Co. Limited (Japan) have filed an International Patent Application for specific “Cannabinoids for the Treatment of Neuropathic Pain”!
The English Abstract is as follows:
“The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.”
This patent claims that it is a novel discovery, however, in the book “Cannabinoids and Terpenes: The Medicinal Benefits of Cannabis“, Ryder Management along with many other patients of medical cannabis, have known this for years.
Reblogged on WordPress.com
Source: What is a hemp seed?
Thanks to Rick Simpson, I now have a profound respect and understanding of the cannabis plant. In addition to many hours devoted to researching the history of this plant, along with testing various strains using a thin layer chromatography (TLC) kit, I am appalled and somewhat frustrated with how Health Canada seems to think that they can insist patients needing medical cannabis will simply rollover and buy cannabis where they dictate. In other words, Ontario needs to take a lesson from those in BC. Stand up and fight for your rights!
Although the constitutional challenge over the right to grow our own plant medicine is presently undecided and therefore, no law presently exists, if our right to grow is taken away, patients will be denied the right to juice this medicinal plant!
It might come as a surprise to many that contrary to the literature, many indica skunk strains we tested, show a higher ratio of the cannabinoids CBG and THCV over the much touted CBD cannabinoid.
What does this mean?
As medical cannabis patients, we must become more discerning and particular when choosing the specific strain of medical cannabis that works best for our individual and unique needs.
The cannabinoids in cannabis work in a synergistic capacity and we should not accept a simplistic standardization that, although facilitates the pharmaceutical industry’s method of monopolistic distribution, ultimately limits what this plant could otherwise offer us in terms of full homeostasis.
In Canada, the ministry that thinks they own our health, has basically handed control of the cannabis plant over to corporate bankers. These suits who were promised a large return on investment, are allowed to use approved pesticides on a plant that was previously grown organically by most approved growers under the old system.
Furthermore, the new licensed growers/producers are also only required to disclose the percentage of only the THC and CBD cannabinoid content, as if those are the only two cannabinoids that exist.
Other Countries have a misconception that Canada is advanced with their new MMPR legislation. Nothing can be further from the truth. Health Canada is selling the patients who need the medicine to big corp who only want to make money through control. Without the right to grow, patients will lose their right to juice, a life saving remedy for numerous disorders.